Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulation

a formulation and peptide technology, applied in the field of formulation, can solve the problem that most induced antibodies are ineffective in preventing infection

Inactive Publication Date: 2012-07-12
DUKE UNIV +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a way to make a formulation that can help create antibodies that can fight HIV-1. The formulation is made by combining a specific part of the HIV-1 virus with a liposome. This invention can help researchers develop better ways to make these antibodies.

Problems solved by technology

Most induced antibodies are ineffective in preventing infection, however, because they are either nonneutralizing or narrowly isolate-specific, and the virus replicates so rapidly that ongoing selection of neutralization-resistant mutants allows viral evolution to “keep ahead” of high-affinity antibody production (Wei et al., Nature 422:307-312 (2003)).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulation
  • Formulation
  • Formulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Description of gp41 MPER Peptide-gp41 Prehairpin Intermediate Conjugates

[0032]FIG. 1 shows the prehairpin intermediate forms of the HIV-1 gp41 MPER that can be conjugated to synthetic liposomes (Frey et al, Proc. Natl. Acad. Sci. 105:3739-3744 (2008)). To produce biochemically homogeneous forms of additional conformations, two constructs were made that were designed to capture gp41 in the extended, prehairpin intermediate conformation. As shown in FIG. 1, gp41-inter has the following sequence: (HR2)-linker-[HR1-CC loop-HR2-MPER]-(trimerization tag), where HR1 and HR2 are the first and second “heptad repeat” in gp41 (the segments that form helices in the postfusion trimer of hairpins) and the sequence in brackets is essentially the complete gp41 ectodomain, except for the fusion peptide. The “linker” is a short, flexible connector of serines and glycines. When gp41-inter chains trimerize, the N-terminal HR2 segments to form a six-helix bundle with the HR1 segments; the C-terminal HR2...

example 2

[0039]Autoreactive B cells can be activated by TLR ligands through a mechanism dependent on dual engagement of the BCR and TLR (Leadbetter et al, Nature 416:603 (2002); Marshak-Rothstein et al, Annu. Rev. Immunol. 25:419-41 (2007), Herlands et al, Immunity 29:249-260 (2008), Schlomchik, Immunity 28:18-28 (2008)). In this immunogen design, soluble IFN-α has been encapsulated into liposomes conjugated to either MPER656 or MPER656-L669S peptides. IFN-α has been reported to modulate and relax the selectivity for autoreactive B cells by lowering the BCR activation threshold (Uccellini et al, J. Immunol. 181:5875 (2008)). The design of these immunogens is also based on the observation that lipid reactivity of gp41 MPER antibodies is required for both binding to membrane bound MPER epitopes and in the neutralization of HIV-1.

[0040]The long CDR H3 loops of MPER neutralizing mAbs 4E10 and 2F5 have a hydrophobic face, postulated to interact with virion membrane lipids (Ofek et al, J. Virol. 7...

example 3

Experimental Details

[0044]Ni-NTA (N″,N″-bis[carboxymethyl]-L-lysine; nitriloacetic acid, NTA) liposomes were constructed from synthetic lipids POPC, POPE, DOGS (1,2 dioleoyl-sn- glycerol-3-succinyl-NTA-Ni) and cholesterol at mole fractions 45, 25, 5 and 25 respectively using methods described earlier (Alam et al., J. Immunol. 178:4424-4435 (2007)). Conjugation of His tagged gp41-inter to the Ni-NTA liposomes was verified by surface plasmon resonance experiment. The His tagged gp41-inter when injected over the immobilized liposomal surfaces bound selectively to the Ni-NTA liposomes when compared to the control liposomes that lacked Ni-NTA. The presentation of epitopes of MPER neutralizing antibodies in the liposome conjugated gp41-inter was examined by comparing the binding of 2F5 and 4E12 mAbs to the gp41-inter bearing Ni-NTA liposomes with that of unconjugated Ni-NTA liposomes. Both 2F5 and 4E10 mAbs bound selectively to the gp41-inter bearing Ni-NTA liposomes

Results

[0045]FIG. 10 s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molar ratioaaaaaaaaaa
axial distanceaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation.

Description

[0001]This application claims priority from U.S. Provisional Application No. 61 / 166,648, filed Apr. 3, 2009, the entire content of which is incorporated herein by reference.[0002]This invention was made with government support under Grant No. AI 067854 awarded by the National Institutes of Health. The government has certain rights in the invention.TECHNICAL FIELD[0003]The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation.BACKGROUND[0004]HIV-1 infection generally induces a strong antibody response to the envelope glycoprotein [trimeric (gp160)3, cleaved to (gp120 / gp41)3], the sole antigen on the virion surface. Most induced antibodies are ineffective in preventing infection, however, becaus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/385A61K38/21A61P31/18A61K9/127
CPCA61K9/127A61K39/21A61K47/48238A61K47/48815C12N2740/16134A61K2039/55522A61K2039/55555A61K2039/55561A61K2039/55511A61K39/12A61K47/62A61K47/6911A61P31/12A61P31/18
Inventor ALAM, S. MUNIRHAYNES, BARTON F.HARRISON, STEPHENCHEN, BING
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com